The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's a funny pond that we're swimming in. I've read that Source Bioscience are going to announce a float on AIM this week.
They have placed a reasonable order recently with EKF, who just happen to be working with Ygen when it comes to testing students in Leicester.
Listen to the last webinar from EKF, and when the question was asked..."why don't you start doing your own testing?"...the answer was something like...it would cost too much and take too long, we leave that to company's like Yourgene.
Strange world, I think there is an awful lot going on beneath the surface.
yes, understand that bakky, I was just pointing out that any deals done for clarigene with companies abroad would be for the accuracy of our test which could lead to millions of tests being sold. No need for the testing service just a huge scal up in manufacturing or as you said partners on board and start getting them distributed.
It is the gold standard!!
Cooper, still being evaluated I expect as no rns to confirm anything. I think it's 10 in total with 8 being abroad. Maybe the TU will clarify things a bit more.
yes NiptSteve, precisely my point. Any contract will be of moderate value unless we can offer much much bigger capacity. Of course we could always use manufacturing partners to help out with hopefully big numbers. Every other supplier is doing just that!
pacman,
if 9 are abroad then that would indicate manufacturing agreements and selling the clarigene test selling in the millions.
I posted a link to a contract given to Source Bioscience valued at £3m and they are ramping up to 10k tests per day so I wouldn’t expect too much from the NHS side of things as our known processing capacity is much less than this - saying that, they have been in discussions for a number of weeks so this gives me hope something a bit bigger is being discussed.
Let’s hope for news this week that contains volumes and capacity plans along with a strong H1 trading update.
LR did mention the Clarigene test was being evaluated by 10 organisations, 9 of which were abroad.
Notbing heard on that front. Hopefully get more clarity in the update, when/if it arrives.
I suppose it depends if we are only using our Clarigene tests for our benefit. If so we are only shifting 10k Clarigene tests a month because we are only doing 10k tests giving us 50 months worth.
However, it remains to be seen if we are shipping some of our clarigene tests to customers who will run there own testing or use a 3rd party.
At the moment we don't know.
Bakky 500k capacity between September and xmas means if we can max out our capacity then your looking at £10- to £12 mill hitting our bottom line by xmas. Individual contracts I have no idea but I'm basing it on what LR states he can achieve and based on £25 per test hitting our bottom line. it could be more.
anyone got any thoughts on what to expect regards a potential contract value ? Personally I am not expecting too much for a couple of reasons. One being we are only recruiting for a six month period, and secondly we don't have too much spare inhouse capacity to offer taking into account the private stuff. I know we are working two shifts but even so we are only a relatively small outfit. I suppose what I'm getting at is we won't get massive numbers like say Ncyt or one or two others. I can't imagine many being too impressed if we get something like £2/3 million deal.